Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY +1.49%77 Future 3-5Y Total Revenue Growth Rate is 5.65 as of Aug. 04, 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 387 Medical Devices & Instruments companies, Coloplast AS ranks worse than 82.69% on this metric.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Coloplast AS's Future 3-5Y Total Revenue Growth Rate is 5.65.
Coloplast AS (OTCPK:CLPBY) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Coloplast AS Future 3-5Y Total Revenue Growth Rate Related Terms
CLPBY vs ISRG, BDX, MDLN: Future 3-5Y Total Revenue Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Future 3-5Y Total Revenue Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Future 3-5Y Total Revenue Growth Rate falls into.
What does a Future 3-5Y Total Revenue Growth Rate of 5.65 mean?
Coloplast AS (CLPBY) has a Future 3-5Y Total Revenue Growth Rate of 5.65 as of Aug. 04, 2026. Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period. View historical data for Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #320 out of 387 companies in the Medical Devices & Instruments industry, placing it in the top 82.7%.
Is Coloplast AS's Future 3-5Y Total Revenue Growth Rate too high?
Coloplast AS's current Future 3-5Y Total Revenue Growth Rate is 5.65. The Medical Devices & Instruments industry median Future 3-5Y Total Revenue Growth Rate is 12.90. Coloplast AS's value of 5.65 is 56.2% below this industry median. Based on the distribution chart, Coloplast AS ranks #320 out of 387 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Future 3-5Y Total Revenue Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #320 out of 387 companies for Future 3-5Y Total Revenue Growth Rate. This places Coloplast AS in the lower half of its industry. The industry median Future 3-5Y Total Revenue Growth Rate is 12.90. Coloplast AS's value of 5.65 is 56.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y Total Revenue Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y Total Revenue Growth Rate among Medical Devices & Instruments companies is 12.90, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y Total Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y Total Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Future 3-5Y Total Revenue Growth Rate of 5.65 is 56.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y Total Revenue Growth Rate mean?
A high Future 3-5Y Total Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period. View historical data for Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y Total Revenue Growth Rate is 12.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Future 3-5Y Total Revenue Growth Rate is 5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.80 — trading 47.9% below its estimated fair value. The current Future 3-5Y Total Revenue Growth Rate is 5.65 and 56.2% below the Medical Devices & Instruments industry median of 12.90. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y Total Revenue Growth Rate calculated?
Future 3-5Y Total Revenue Growth Rate is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Future 3-5Y Total Revenue Growth Rate is 5.65 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.80 is trading 47.9% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Future 3-5Y Total Revenue Growth Rate: 5.65
GF Value™: $13.05 vs. price of $6.80 (47.9% below fair value)
Industry Position: 56.2% below the Medical Devices & Instruments median (#320 of 387)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Future 3-5Y Total Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
